120 related articles for article (PubMed ID: 37688463)
1. Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort.
Yang J; Meng L; Yang Y; Gao H; Jiang H
Nucleosides Nucleotides Nucleic Acids; 2024; 43(3):230-248. PubMed ID: 37688463
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women.
Karami S; Sattarifard H; Kiumarsi M; Sarabandi S; Taheri M; Hashemi M; Bahari G; Ghavami S
Asian Pac J Cancer Prev; 2020 Oct; 21(10):3115-3123. PubMed ID: 33112575
[TBL] [Abstract][Full Text] [Related]
3. Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer.
Tan D; Sheng L; Yi QH
Cancer Biomark; 2018 Feb; 21(2):287-297. PubMed ID: 29171986
[TBL] [Abstract][Full Text] [Related]
4. PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma.
Kasamatsu T; Awata M; Ishihara R; Murakami Y; Gotoh N; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Saitoh T; Murakami H
Clin Exp Med; 2020 Feb; 20(1):51-62. PubMed ID: 31620907
[TBL] [Abstract][Full Text] [Related]
5. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
Kearl TJ; Jing W; Gershan JA; Johnson BD
J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
[TBL] [Abstract][Full Text] [Related]
6. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
[TBL] [Abstract][Full Text] [Related]
7. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
Luo L; Shu M; Li S; Cai Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
[TBL] [Abstract][Full Text] [Related]
8. Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression.
Xuan Hoan N; Thi Minh Huyen P; Dinh Tung B; Phuong Giang D; Tat Trung N; Tien Sy B; Thi Tuan N; Thi Ngoc Dung D; Reddy Pallerla S; Velavan TP; Hong Bang M; Huu Song L
Gene; 2022 Jan; 806():145935. PubMed ID: 34478821
[TBL] [Abstract][Full Text] [Related]
9. [Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications].
Zhang P; Ouyang S; Wang J; Huang Z; Wang J; Liao L
Hua Xi Kou Qiang Yi Xue Za Zhi; 2015 Oct; 33(5):529-33. PubMed ID: 26688950
[TBL] [Abstract][Full Text] [Related]
10. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
11. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
12. Percentages of PD-1
Wang Y; Pang N; Wang X; Liu Y; Wang X; Wang L; Sun M; Yasen H; Zhao F; Fan W; Guo X; Ding J
Hum Vaccin Immunother; 2018 Apr; 14(4):832-838. PubMed ID: 29333980
[TBL] [Abstract][Full Text] [Related]
13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
14. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
Zhang X; Lu H; Peng L; Zhou J; Wang M; Li J; Liu Z; Zhang W; Zhao Y; Zeng X; Lu L
Rheumatology (Oxford); 2022 Feb; 61(2):815-825. PubMed ID: 33930105
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1/PD-L1 pathway in multiple myeloma.
Zhang J; Liu Z; Cao P; Wang H; Liu H; Hua L; Xue H; Fu R
Cancer Med; 2022 Dec; 11(24):4838-4848. PubMed ID: 35593325
[TBL] [Abstract][Full Text] [Related]
16. The blockage signal for PD-L1/CD274 gene variants and their potential impact on lung carcinoma susceptibility.
Sakran MI; Alalawy AI; Alharbi AA; El-Hefnawy ME; Alzahrani SM; Alfuraydi A; Alzuaibr FM; Zidan NS; Elsaid AM; Toraih EA; Elshazli RM
Int Immunopharmacol; 2023 Dec; 125(Pt A):111180. PubMed ID: 37939515
[TBL] [Abstract][Full Text] [Related]
17. The significance of PD-1/PD-L1 imbalance in ulcerative colitis.
Shi W; Zhang Y; Hao C; Guo X; Yang Q; Du J; Hou Y; Cao G; Li J; Wang H; Fang W
PeerJ; 2023; 11():e15481. PubMed ID: 37273534
[TBL] [Abstract][Full Text] [Related]
18. [Effect of dendritic cells on immune function regulated by programmed cell death-1/programmed cell death-ligand 1 in sepsis].
Wang Z; Xie Z; Zhao Y; Bu T; Yu A; Wang S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Sep; 33(9):1032-1039. PubMed ID: 34839857
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
[TBL] [Abstract][Full Text] [Related]
20. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
Brusa D; Serra S; Coscia M; Rossi D; D'Arena G; Laurenti L; Jaksic O; Fedele G; Inghirami G; Gaidano G; Malavasi F; Deaglio S
Haematologica; 2013 Jun; 98(6):953-63. PubMed ID: 23300177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
